Clinical Trial Detail

NCT ID NCT02365662
Title A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements yes
Sponsors AbbVie
Indications

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

glioblastoma multiforme

Advanced Solid Tumor

Therapies

ABBV-221

Age Groups: adult

Additional content available in CKB BOOST